Drugs for Malaria and HIV/AIDS a High Priority
ADDIS ABABA, Ethiopia, Jan. 21 /PRNewswire-FirstCall/ -- Rx for Africa, Inc.'s (Pink Sheets: RXAF.PK) wholly owned operating subsidiary, Rx Africa (Ethiopia) P.L.C. announced today that it's newly completed R&D center has formulated nine generic pharmaceuticals, and is on track to launch a minimum of 36 new products in calendar 2009. The state of the art malaria drug Artemisinin is scheduled for a third-quarter launch, and HIV/AIDS pharmaceuticals are in process. "Globally, malaria is responsible for more than one million deaths per year, with 90% of these deaths here in sub-Saharan Africa. Over 22 million Africans live with HIV/AIDS, and 1.5 million a year die from it," said Dr. Mulugetta Bezzabeh, the CEO of Rx for Africa, Inc. "The urgency of meeting such crucial health needs is why we are so diligent in working towards our production goals."
"Additionally, our launch list of generic pharmaceuticals includes many standard antibiotics, anti-fungals, anti-inflammatory and analgesic drugs that are taken for granted in the U.S. and developed world, but of which there are still extreme shortages in Ethiopia, and throughout Sub-Saharan Africa. Our staff in Ethiopia, including scientists from India and Germany, is now accomplishing this important work and meeting or exceeding scheduling milestones."
About Rx for Africa, Inc.
Rx for Africa, Inc. is a public New Jersey corporation, formed in 2007 to invest in companies manufacturing generic pharmaceuticals in Sub-Saharan Africa. Rx Africa (Ethiopia) P.L.C. is a wholly-owned operating subsidiary of Rx for Africa, Inc., with a campus just outside Addis Ababa, Ethiopia, comprising a factory, R&D center and office facilities, currently producing six generic pharmaceutical products. The company sells 100% of its current production through distributors. Shares of Rx for Africa, Inc. com
|SOURCE Rx for |
Copyright©2009 PR Newswire.
All rights reserved